KTKevin M. Truong-Balderas

Kevin M. Truong-Balderas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin M. Truong-Balderas has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immune‐Excluded Mucosal Melanoma: Spatial Mechanisms of Checkpoint Resistance and Biomarker‐Guided Therapeutic Opportunities

    by Kevin M. Truong‐Balderas, Rachel C. Chang, Claudia Lasalle, Meredith C. Rogers, Yulu Wang, Kyle T. Amber, Adrian P. Mansini

    Mucosal melanoma is a rare, aggressive melanoma subtype arising from melanocytes within mucosal surfaces of the head and neck, anorectal, gastrointestinal, and genitourinary tracts. Unlike ultraviolet‐driven cutaneous melanoma, mucosal melanoma has lower tumor mutational burden, fewer BRAF V600 alterations, greater structural genomic complexity, and recurrent drivers including mutations in KIT, NRAS, NF1, SF3B1, and copy‐number alterations. It is often diagnosed at advanced stages, recurs locally, disseminates early, and responds less favorably to immune checkpoint inhibition than cutaneous melanoma. Low neoantigen burden contributes to this resistance, but emerging evidence indicates that antitumor immunity is also shaped by spatially organized tumor‐immune interactions, site‐specific mucosal biology, suppressive myeloid and stromal programs, angiogenic signaling, and underexplored innate checkpoint pathways. Here, we review mucosal melanoma as a biologically distinct model of immune‐excluded melanoma, summarizing its clinical behavior, genomic architecture, immunotherapy outcomes, and mechanisms of checkpoint resistance, with emphasis on restricted intratumoral CD8‐positive T‐cell infiltration, macrophage‐ and stroma‐rich barriers, angiogenic remodeling, and candidate innate checkpoints including B7‐H3, CD24–Siglec‐10, CD47–SIRPα, and B7‐H6/NKp30. We further discuss how spatial and circulating biomarkers may support response‐adapted translational studies and define actionable immune states across mucosal melanoma sites.

  • Keratinocyte Autophagy in Inflammatory Dermatoses: Mechanisms, Disease‐Specific Programs and Therapeutic Opportunities

    by Yulu Wang, Kevin M. Truong‐Balderas, Yi Gao, Claudia Lasalle, Sabrina Schundler, Bethany E. Perez White, Kyle T. Amber, Adrian P. Mansini

    Autophagy is increasingly recognised as a regulator of epithelial stress adaptation in the skin, but its role in inflammatory dermatoses remains difficult to interpret because autophagy intersects with barrier biology, keratinocyte differentiation, immune signalling, intracellular trafficking and lysosomal degradation. Keratinocytes are immune‐competent epithelial cells that integrate cytokine exposure, oxidative stress, microbial sensing and tissue injury into inflammatory output. In this review, we synthesize evidence on keratinocyte autophagy as a disease‐dependent regulator of epidermal homeostasis and cutaneous inflammation. We summarize core autophagy machinery, selective autophagy programs relevant to epidermal differentiation and the interpretive value of autophagic flux and lysosomal competence. We then discuss how autophagy influences keratinocyte differentiation, organelle clearance, lipid handling, barrier support, inflammatory restraint and stress adaptation. Disease‐specific evidence is reviewed in psoriasis, AP1S3‐associated pustular autoinflammation, atopic dermatitis and vitiligo. Across these settings, keratinocyte autophagy cannot be classified as uniformly protective or pathogenic; its effects depend on inflammatory context, trafficking state, cell‐type‐specific outputs and the ability of lysosomes to complete degradation. We also consider lessons from other barrier epithelia, therapeutic implications and common methodological limitations. A keratinocyte‐centered, flux‐aware interpretation provides a framework for organizing disease‐specific autophagy biology and for designing more rigorous mechanistic studies in inflammatory dermatoses.

  • Open Access

    B7-H6/NKp30 Axis in Melanoma: Translational Rationale, Evidence Gaps, and Therapeutic Considerations

    by Kevin M. Truong-Balderas, Rachel C. Chang, Claudia Lasalle, Yi Gao, Nicole C. Nowak, Kyle T. Amber, Adrian P. Mansini

    Melanoma treatment has been transformed by immune checkpoint blockade, yet many patients still experience primary resistance, limited durability of response, or acquired resistance. These limitations underscore the need for additional targets that reflect melanoma biology while enabling new therapeutic strategies, particularly in biologically defined settings of immune escape such as checkpoint-resistant, HLA-low, dedifferentiated, or stress-adapted melanoma. The B7-H6/NKp30 axis has gained attention as a link between tumor cell stress, immune recognition, and therapy-related adaptation. B7-H6 (NCR3LG1), an inducible ligand for NKp30, has been detected in melanoma cell lines and tumor specimens, and soluble B7-H6 has been identified in a subset of patients. Membrane-bound B7-H6 may support NK-cell activation, whereas ligand shedding and accumulation of soluble B7-H6 may reduce effective antitumor recognition and promote immune evasion. Emerging evidence further suggests that B7-H6 expression may be linked to tumor-intrinsic programs relevant to melanoma cell survival, migration, and adaptation to therapeutic stress. However, B7-H6 is not yet a validated predictive biomarker or an established therapeutic target in melanoma, and current evidence remains limited by small melanoma-specific datasets, incomplete information on spatial and temporal heterogeneity, and the absence of melanoma-focused clinical validation. In this review, we examine the role of the B7-H6/NKp30 axis in immune surveillance, tumor escape, biomarker development, and therapeutic targeting, and discuss its translational potential in melanoma as an emerging but incompletely validated pathway that warrants focused investigation in melanoma states where conventional immune control is limited.


  • Open Access

    B7-H6/NKp30 Axis in Melanoma: Immune Surveillance, Tumor Escape, and Therapeutic Targeting

    by Kevin M. Truong-Balderas, Rachel C. Chang, Claudia Lasalle, Yi Gao, Nicole C. Nowak, Kyle T. Amber, Adrian P. Mansini

    Melanoma treatment has been transformed by immune checkpoint blockade, yet many patients still experience primary resistance, limited durability of response, or acquired resistance. These limitations underscore the need for additional targets that reflect melanoma biology while enabling new therapeutic strategies. The B7-H6/NKp30 axis has gained attention as a link between tumor cell stress, immune recognition, and therapy-related adaptation. B7-H6 (NCR3LG1), an inducible ligand for NKp30, has been detected in melanoma cell lines and tumor specimens, and soluble B7-H6 has been identified in a subset of patients. Membrane-bound B7-H6 may support NK-cell activation, whereas ligand shedding and accumulation of soluble B7-H6 may reduce effective antitumor recognition and promote immune evasion. Emerging evidence further suggests that B7-H6 expression may be linked to tumor-intrinsic programs relevant to melanoma cell survival, migration, and adaptation to therapeutic stress. In this review, we examine the role of the B7-H6/NKp30 axis in immune surveillance, tumor escape, biomarker development, and therapeutic targeting, and discuss its translational potential in melanoma.

  • Frequency of venous thromboembolism in immunobullous disease patients treated with IVIG: A systematic review

    by Kevin Truong‐Balderas, Nicole Nowak, Paige Adams, Jennifer Westrick, Lorena Juarez, Schuyler Hilton, Kyle T. Amber

  • Prevalence of comorbidities and thromboembolic events in individuals with Autoimmune Bullous diseases

    by Sierra Thomas, Kevin Truong-Balderas, Joseph McGrath, Joe Jackson, Tanner Sanberg, Erin X. Wei